Literature DB >> 27246696

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy.

Geoffrey Dusheiko1,2, Bo Wang3, Ivana Carey3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27246696     DOI： 10.1007/s12072-016-9738-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  21 in total

Review 1.  Hepatitis B surface antigen seroclearance during chronic HBV infection.

Authors:  Chia-Ming Chu; Yun-Fan Liaw
Journal:  Antivir Ther       Date:  2010

2.  Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

Authors:  Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Norio Akuta; Takashi Someya; Tetsuya Hosaka; Hitomi Sezaki; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

3.  In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.

Authors:  Xiaonan Zhang; Wei Lu; Ye Zheng; Weixia Wang; Lu Bai; Liang Chen; Yanling Feng; Zhanqing Zhang; Zhenghong Yuan
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

4.  New perspectives on the hepatitis B virus life cycle in the human liver.

Authors:  Peter A Revill; Stephen A Locarnini
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

5.  Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Chia-Chi Wang; Chi-Ling Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2011-04-28       Impact factor: 22.682

6.  Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.

Authors:  Jessica Liu; Hwai-I Yang; Mei-Hsuan Lee; Sheng-Nan Lu; Chin-Lan Jen; Li-Yu Wang; San-Lin You; Uchenna H Iloeje; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

7.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

8.  HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.

Authors:  Man-Fung Yuen; Danny Ka-Ho Wong; Erwin Sablon; Eric Tse; Irene Oi-Lin Ng; He-Jun Yuan; Chung-Wah Siu; Tamara J Sander; Eric J Bourne; Jeff G Hall; Lynn D Condreay; Ching-Lung Lai
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

9.  Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.

Authors:  Wai-Kay Seto; Thomas S Y Chan; Yu-Yan Hwang; Danny Ka-Ho Wong; James Fung; Kevin Sze-Hang Liu; Harinder Gill; Yuk-Fai Lam; Albert K W Lie; Ching-Lung Lai; Yok-Lam Kwong; Man-Fung Yuen
Journal:  J Clin Oncol       Date:  2014-10-06       Impact factor: 44.544

10.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.

Authors:  Gi-Ae Kim; Young-Suk Lim; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Dong Jin Suh
Journal:  Gut       Date:  2013-10-25       Impact factor: 23.059
View more
  3 in total

1.  Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.

Authors:  Jonathan Quinet; Catherine Jamard; Madeleine Burtin; Matthieu Lemasson; Sylviane Guerret; Camille Sureau; Andrew Vaillant; Lucyna Cova
Journal:  Hepatology       Date:  2018-02-23       Impact factor: 17.425

2.  Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.

Authors:  Min Zhang; Guangdi Li; Jia Shang; Chen Pan; Minxiang Zhang; Zhibiao Yin; Qing Xie; Yanzhong Peng; Qing Mao; Xinqiang Xiao; Yongfang Jiang; Kaizhong Luo; Yun Xu; Hai Ding; Wenzhou Fan; Vidaurre Diego; Mahmoud Reza Pourkarim; Erik De Clercq; Guiqiang Wang; Guozhong Gong
Journal:  Hepatol Int       Date:  2020-02-25       Impact factor: 6.047

3.  Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure.

Authors:  Fraence Hardtstock; Urbano Sbarigia; Zeki Kocaata; Thomas Wilke; Shirley V Sylvester
Journal:  Patient Prefer Adherence       Date:  2020-03-19       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.